.With early phase 1 data right now out in bush, metabolic disease ensemble Metsera is actually losin...
.Rivus Pharmaceuticals has unveiled the information responsible for its own phase 2 obesity succeed ...
.Bristol Myers Squibb is paying Main Medicine $110 million ahead of time to develop reagents for ex ...
.Novartis has inked a package possibly worth much more than $1 billion along with Flagship-founded G...
.Recently debuted Metsera is unfolding some stage 1 record for its GLP-1 receptor agonist, disclosin...
.Amid the genetic medicines branches ethnicity, Main Pioneering is revealing a new business to help ...
.BioAge Labs is looking at all around $180 million in preliminary profits from an IPO and also a pri...
.A try through Merck & Co. to unlock the microsatellite secure (MSS) metastatic colon cancer mark...
.Spain-based Asabys Partners has shut a fund of 180 thousand euros ($ 200 thousand), money that will...
.BioAge Labs is actually bringing in just about $200 million through its own Nasdaq IPO this morning...